8 Feb 2024 , 03:21 PM
Result date: February 10, 2024
Recommendation: Reduce
Target price: ₹3,160
Analysts at IIFL Securities believe Divi’s Laboratories could post revenue growth of 6% sequentially and 18% over the year-ago quarter. This will be driven by 4/9% sequential revenue growth in the Generic/CS segment, as the CS segment is likely to benefit from the fast-track Contrast Media project (Iopromide).
Analysts at IIFL Securities have also factored-in the company’s EBITDA margins to improve ~340 basis points sequentially to 29.5%, driven by sequential growth in the CS segment and stabilization in raw material prices. They expect nil contribution from Molnu in Q3FY24 versus $2mn in the year-ago quarter.
Profit After Tax or PAT could improve 39% over the year-ago quarter and 16% sequentially.
Important management insights to watch out for:
₹ Million |
December 2023 estimates |
YoY change |
QoQ change |
Revenue |
20,150 |
18.0% |
5.6% |
Generic revenue* |
11,863 |
15.8% |
3.6% |
CS |
8,287 |
21.3% |
8.5% |
EBITDA |
5,944 |
45.6% |
19.1% |
EBITDA margin |
29.5% |
559 bps |
336 bps |
Profit After Tax |
4,256 |
38.7% |
15.7% |
Source: IIFL Research
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.